Adaptive Biotechnologies Isn't Quite Your Portfolio's Immune Booster

Bashar Issa profile picture
Bashar Issa


  • ADPT is, in my opinion, still too early in its development cycle to warrant a buy recommendation.
  • That being said, I believe the company is moving in the right direction and am excited to see what it will deliver in the long term.
  • ADPT has a strong balance sheet, and I expect the company to maintain its current funding structure for at least until 2025.

Fruits and vegetables for immune system boosting. Healthy eating background with copy space. Top view

Maglara/iStock via Getty Images

Investment Thesis

Adaptive Biotechnologies (NASDAQ:ADPT) developed a system for parsing the genetic data stored in our adaptive immune systems in order to provide targeted diagnostics and therapies. The company's platform can make products for three

This article was written by

Bashar Issa profile picture
Bashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bachelor's degree in Economics from Middlesex University.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.